Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Adult
Attitude
Drug Overdose
/ drug therapy
Female
Harm Reduction
Humans
Male
Middle Aged
Naloxone
/ supply & distribution
Narcotic Antagonists
/ supply & distribution
New England
/ epidemiology
Opioid-Related Disorders
/ drug therapy
Pharmacies
Qualitative Research
Risk Factors
Social Stigma
Socioeconomic Factors
Interviews
Naloxone
Opioid
Overdose
Pharmacy
Qualitative
USA
Journal
Journal of urban health : bulletin of the New York Academy of Medicine
ISSN: 1468-2869
Titre abrégé: J Urban Health
Pays: United States
ID NLM: 9809909
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
13
2
2019
medline:
4
8
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Drug overdose is the leading cause of unintentional death in the USA and the majority of deaths involve an opioid. Pharmacies are playing an increasingly important role in getting naloxone-the antidote to an opioid overdose-into the community. The aim of the current study was to understand, from the perspective of those who had obtained naloxone at the pharmacy, whose drug using status and pain patient status was not known until the interviews were conducted, as well as those who had not obtained naloxone at the pharmacy but were at risk for overdose, factors that impact the likelihood of obtaining pharmacy-based naloxone (PBN). Fifty-two participants from two New England states were interviewed between August 2016 and April 2017. We used a phenomenological approach to investigate participants' beliefs about pharmacy-based naloxone. The social contextual model was chosen to structure the collection and analysis of the qualitative data as it takes into account individual, interpersonal, organizational (pharmacy), community, and societal influences on a specific health behavior. Of the 52 people interviewed, 24 participants had obtained naloxone from the pharmacy in the past year, of which 4% (n = 1) self-disclosed during the interview current illicit drug use and 29% (n = 7) mentioned using prescribed opioid pain medication. Of the 28 people who had not obtained naloxone from the pharmacy, 46% (n = 13) had obtained an over the counter syringe from a pharmacy in the past month and had used an opioid in the past month, and 54% (n = 15) had used a prescribed opioid pain medication in the past month but did not report a syringe purchase. Several main themes emerged from the interview data. Individual-level themes were as follows: helplessness and fear, naloxone as empowerment to help, and past experiences at the pharmacy. Interpersonal-level themes were as follows: concern for family and friends, and sources of harm reduction information. Themes associated with pharmacy-level influence were as follows: perceived stigma from pharmacists, confusion at the pharmacy counter, and receptivity to pharmacists' offer of naloxone; community-level themes were as follows: community caretaking and need for education and training. Finally, themes at the societal-level of influence were as follows: generational crisis, and frustration at lack of response to opioid crisis. Overall our findings reveal factors at multiple levels which may play a role in likelihood of obtaining naloxone at the pharmacy. These factors can be used to inform interventions seeking to increase provision of pharmacy-based naloxone.
Identifiants
pubmed: 30747371
doi: 10.1007/s11524-019-00349-1
pii: 10.1007/s11524-019-00349-1
pmc: PMC6565759
doi:
Substances chimiques
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-378Subventions
Organisme : AHRQ HHS
ID : R18 HS024021
Pays : United States
Références
Prev Med. 2003 Sep;37(3):188-97
pubmed: 12914824
Qual Health Res. 2007 Dec;17(10):1372-80
pubmed: 18000076
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Harm Reduct J. 2015 Aug 06;12:25
pubmed: 26245865
J Addict Med. 2016 Sep-Oct;10(5):300-8
pubmed: 27261669
J Addict Med. 2017 Jan/Feb;11(1):1-2
pubmed: 27898497
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S34-S44
pubmed: 28189540
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S19-S27.e4
pubmed: 28214219
N C Med J. 2018 May-Jun;79(3):149-155
pubmed: 29735615
Drug Alcohol Depend. 2018 Jul 1;188:187-192
pubmed: 29778772
JAMA. 2018 Nov 13;320(18):1933-1934
pubmed: 30422185